Our Stem Cell Treatment for Arthritis consists of developing a structure with new potent cells that will mimick the proper function of the musculoskeletal system while providing support for the body and aiding it in its movements. Stem cells have the ability to produce regulatory T cells, a type of immune cell whose responsibility is to regulate the immune system while maintaining tolerance to self-antigens. By differentiating into these types of healthy cells there is a possibility that adult mesenchymal cells will be able to address the complications caused by Arthritis.
Our stem cell therapy for arthritis is a minimally invasive procedure and the delivery method used is: IV implantation. While many clinics offer IV stem cells, very few have an in-depth understanding of how variations in concentration, speed and volume can affect the efficacy of a stem cell treatment, as well as the amount of cells that are able to migrate to the target organ or tissue. Our highly experienced group of researchers and physicians, through years of applied research and clinical experience have been able to determine the specific concentrations of stem cells, volume of carrier fluids and speed of infusion to optimize IV treatments for each specific condition treated. Everything from taking advantage of physiological phenomena like the “First-pass lung effect” to concentration-based absorption rates are taken into account in order to find the best possible method of infusion for each specific patient.
Arthritis FAQ’s
Wharton’s jelly-derived stem cells (WJ-MSCs) are mesenchymal stem cells obtained from the gelatinous substance in the umbilical cord, known for their strong anti-inflammatory and regenerative properties. These cells are used in arthritis treatment through two primary methods: direct injection into affected joints and intravenous (IV) administration. When injected directly into the joint, WJ-MSCs help reduce local inflammation, slow cartilage degradation, and promote tissue repair by secreting growth factors that stimulate the regeneration of damaged cartilage and synovial tissue. IV administration, on the other hand, allows the stem cells to circulate throughout the body, modulating the immune system and reducing systemic inflammation, which can be beneficial for patients with widespread or autoimmune-related arthritis, such as rheumatoid arthritis. Unlike other stem cell sources, WJ-MSCs are easy to obtain non-invasively and have a lower risk of immune rejection, making them a promising and accessible option for arthritis therapy.